SEARCH

SEARCH BY CITATION

References

  • Alvers K. M., Beckmann J. S., Zheng G., Crooks P. A., Dwoskin L. P. and Bardo M. T. (2012) The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats. Psychopharmacology 224, 255262.
  • Beckmann J. S., Denehy E. D., Zheng G., Crooks P. A., Dwoskin L. P. and Bardo M. T. (2012) The effect of novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. Psychopharmacology 220, 395403.
  • Benwell M. E. and Balfour D. J. (1998) The influence of lobeline on nucleus accumbens dopamine and locomotor responses to nicotine in nicotine-pretreated rats. Br. J. Pharmacol. 125, 11151119.
  • Besson M., David V., Baudonnat M., Cazala P., Guilloux J. P., Reperant C., Cloez-Tayarani I., Changeux J. P., Gardier A. M. and Granon S. (2012) Alpha7-nicotinic receptors modulate nicotine-induced reinforcement and extracellular dopamine outflow in the mesolimbic system in mice. Psychopharmacology 220, 114.
  • Brown J. M., Hanson G. R. and Fleckenstein A. E. (2000) Methamphetamine rapidly decreases vesicular dopamine uptake. J. Neurochem. 74, 22212223.
  • Brown J. M., Hanson G. R. and Fleckenstein A. E. (2001) Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J. Pharmacol. Exp. Ther. 296, 762767.
  • Champtiaux N., Gotti C., Cordero-Erausquin M. et al. (2003) Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J. Neurosci. 23, 78207829.
  • Dani J. A., Jenson D., Broussard J. I. and De Biasi M. (2011) Neurophysiology of nicotine addiction. J. Addict. Res. Ther. S1, pii.
  • Davidson C., Lee T. H. and Ellinwood E. H. (2005) Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences. Neurochem. Int. 46, 189203.
  • Devoto P., Flore G., Saba P., Bini V. and Gessa G. L. (2013) The dopamine beta-hydroxylase inhibitor nepicastat increases dopamine release and potentiates psychostimulant-induced dopamine release in the prefrontal cortex. Addict. Biol. doi:10.1111/adb. 12026 [Epub ahead of print].
  • Di Chiara G. D. (1995) The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend. 38, 95137.
  • Dwoskin L. P. and Crooks P. A. (2002) A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem. Pharmacol. 63, 8998.
  • Eisenhofer G., Kopin I. J. and Goldstein D. S. (2004) Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol. Rev. 56, 331349.
  • Eyerman D. J. and Yamamoto B. K. (2005) Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum. J. Pharmacol. Exp. Ther. 312, 160169.
  • Fleckenstein A. E., Volz T. J., Riddle E. L., Gibb J. W. and Hanson G. R. (2007) New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol. 47, 681698.
  • Garces-Ramirez L., Green J. L., Hiranita T. et al. (2011) Sigma receptor agonists: receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis. Biol. Psychiatry 69, 208217.
  • Gordon S. L., Quinsey N. S., Dunkley P. R. and Dickson P. W. (2008) Tyrosine hydroxylase activity is regulated by two distinct dopamine-binding sites. J. Neurochem. 106, 16141623.
  • Guillot T. S. and Miller G. W. (2009) Protective actions of vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol. Neurobiol. 30, 149170.
  • Harrod S. B., Dwoskin L. P., Crooks P. A., Klebaur J. E. and Bardo M. T. (2001) Lobeline attenuates d-methamphetamine self-administration in rats. J. Pharmacol. Exp. Ther. 298, 172179.
  • Harrod S. B., Dwoskin L. P., Green T. A., Gehrke B. J. and Bardo M. T. (2003) Lobeline does not serve as a reinforcer in rats. Psychopharmacology 165, 397494.
  • Horton D. B., Siripurapu K. B., Zheng G., Crooks P. A. and Dwoskin L. P. (2011) Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. J. Pharmacol. Exp. Ther. 339, 286297.
  • Karobath M. (1971) Catecholamines and the hydroxylation of tyrosine in synaptosomes isolated from rat brain. Proc. Natl Acad. Sci. USA 68, 23702373.
  • Keath J. R., Iacoviello M. P., Barrett L. E., Mansvelder H. D. and McGehee D. S. (2007) Differential modulation by nicotine of substantia nigra versus ventral tegmental area dopamine neurons. J. Neurophysiol. 98, 33883396.
  • Kumer S. C. and Vrana K. E. (1996) Intricate regulation of tyrosine hydroxylase activity and gene expression. J. Neurochem. 67, 443462.
  • Larsen K. E., Fon E. A., Hastings T. G., Edwards R. H. and Sulzer D. (2002) Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J. Neurosci. 22, 89518960.
  • Mantle T. J., Tipton K. F. and Garrett N. J. (1976) Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem. Pharmacol. 25, 20732077.
  • Miller D. K., Crooks P. A. and Dwoskin L. P. (2000) Lobeline inhibits nicotine-evoked [3H]dopamine overflow from rat striatal slices and nicotine-evoked (86)Rb(+) efflux from thalamic synaptosomes. Neuropharmacology 39, 26542662.
  • Miller D. K., Crooks P. A., Teng L., Witkin J. M., Munzar P., Goldberg S. R., Acri J. B. and Dwoskin L. P. (2001) Lobeline inhibits the neurochemical and behavioral effects of amphetamine. J. Pharmacol. Exp. Ther. 296, 10231034.
  • Miller D. K., Lever J. R., Rodvelt K. R., Baskett J. A., Will M. J. and Kracke G. R. (2007) Lobeline, a potential pharmacotherapy for drug addiction, binds to mu opioid receptors and diminishes the effects of opioid receptor agonists. Drug Alcohol Depend. 89(2–3), 282291.
  • Nakagawa T., Suzuki Y., Nagayasu K., Kitaichi M., Shirakawa H. and Kaneko S. (2011) Repeated exposure to methamphetamine, cocaine or morphine induces augmentation of dopamine release in rat mesocorticolimbic slice co-cultures. PLoS ONE 6, e24865.
  • Narita M., Takagi M., Aoki K., Kuzumaki N. and Suzuki T. (2003) Implication of Rho-associated kinase in the elevation of extracellular dopamine levels and its related behaviors induced by methamphetamine in rats. J. Neurochem. 86, 273282.
  • Nickell J. R., Krishnamurthy S., Norrholm S., Deaciuc G., Siripurapu K. B., Zheng G., Crooks P. A. and Dwoskin L. P. (2010) Lobeline inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2. J. Pharmacol. Exp. Ther. 332, 612621.
  • Paxinos G. and Watson C. (1998) The rat Brain in Stereotaxic Coordinates, 6th ed. Academic Press, London.
  • Rocha A. and Kalivas P. W. (2010) Role of the prefrontal cortex and nucleus accumbens in reinstating methamphetamine seeking. Eur. J. Neurosci. 31, 903909.
  • Rothman R. B. (1999) Is phentramine an inhibitor of monoamine oxidase? A critical appraisal. Synapse 32, 141145.
  • Shimosato K., Nagao N., Watanabe S. and Kitayama S. (2003) Suppressive effects of trihexyphenidyl on methamphetamine-induced dopamine release as measured by in vivo microdialysis. Synapse 49, 4754.
  • Shoblock J. R., Sullivan E. B., Maisonneuve I. M. and Glick S. D. (2003) Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats. Psychopharmacology 165, 359369.
  • Sulzer D., Chen T. K., Lau Y. Y., Kristensen H., Rayport S. and Ewing A. (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15, 41024108.
  • Sulzer D., Sonder M. S., Poulsen N. W. and Galli A. (2005) Mechanism of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 75, 406433.
  • Teng L., Crooks P. A., Sonsalla P. K. and Dwoskin L. P. (1997) Lobeline and nicotine evoke [3H]overflow from rat striatal slices preloaded with [3H]dopamine: differential inhibition of synaptosomal and vesicular [3H]dopamine uptake. J. Pharmacol. Exp. Ther. 280, 14321444.
  • Teng L., Crooks P. A. and Dwoskin L. P. (1998) Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine. J. Neurochem. 71, 258265.
  • Vocci F. J. and Appel N. M. (2007) Approaches to the development of medications for the treatment of methamphetamine dependence. Addiction 102(Suppl 1), 96106.
  • Vollm B. A., de Araujo I. E., Cowen P. J., Rolls E. T., Kringelbach M. L., Smith K. A., Jezzard P., Heal R. J. and Matthews P. M. (2004) Methamphetamine activates reward circuitry in drug naïve human subjects. Neuropsychopharmacology 29, 17151722.
  • Wilhelm C. J., Johnson R. A., Eshleman A. J. and Janowsky A. (2008) Lobeline effects on tonic and methamphetamine-induced dopamine release. Biochem. Pharmacol. 75, 14111415.
  • Zetterstrom T., Sharp T., Collin A. K. and Ungerstedt U. (1988) In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC. Eur. J. Pharmacol. 148, 327334.
  • Zheng G., Dwoskin L. P., Deaciuc A. G., Norrholm S. D. and Crooks P. A. (2005) Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter. J. Med. Chem. 25, 55515560.
  • Zheng G., Dwoskin L. P. and Crooks P. A. (2006) Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J. 8, E682E692.